ACET Adicet Bio, Inc.

NEUTRAL Impact: 3/10 144
Horizon days Filed Apr 8, 2026 Processed 2mo ago SEC 0000947871-26-000413
Form 144 — notice of proposed sale of securities
Latest settled — T+20d ⚠ clustered
ACET ▲ +29.92% at T+20d
NEUTRAL call ✓ call won +29.92% · α vs SPY +21.38% · entry $6.55 → $8.51
Next anchor: T+60d in 22d
Last close $7.22 (close Jun 8) · +10.23% from $6.55 entry
Entry anchored
Apr 7, 03:59 PM ET
via Databento tick
T+1d
+4.73%
call +4.73% · α +4.16%
$6.86
settled 2mo ago
T+5d
+20.92%
call +20.92% · α +17.40%
$7.92
settled 8w ago
T+20d
+29.92%
call +29.92% · α +21.38%
$8.51
settled 5w ago
T+60d
call — · α —
in 22d

Price Chart

Loading chart...

Executive Summary

OrbiMed Israel GP Ltd., the general partner of OrbiMed Israel Partners Limited Partnership, filed a Form 144 to notify intent to sell up to 64,242 shares of Adicet Bio, Inc. (ACET) common stock. The filing is a routine notice of potential sale by an institutional holder and does not confirm that the sale will occur.

Actionable Insight

Monitor for actual sales via future Form 4 or Form 144 filings; this notice alone is not a sale and is typical for institutional holders managing positions. Given the small size relative to market cap, significant price impact is unlikely unless part of a broader exit pattern.

Key Facts

  • Reporting entity: OrbiMed Israel GP Ltd., acting as general partner for OrbiMed Israel Partners Limited Partnership
  • Number of shares proposed for sale: 64,242
  • Security type: Common stock
  • Filing date: April 7, 2026
  • Method of sale: Not specified in filing
  • Relationship: Institutional shareholder, not an officer or director of ACET

Financial Impact

Approximately $2.6 million based on current market price ($41.31 per share), representing a small fraction of ACET's $66M market cap

floatpotential dilutioninsider ownership

Risk Factors

  • Potential downward pressure on stock if sale is executed near-term, especially given ACET's low market cap
  • Perception of reduced confidence by a major institutional holder, though OrbiMed remains invested

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0000947871-26-000413
Document: 0000947871-26-000413-index.html0000947871-26-000413
Document: 0000947871-26-000413.txt0000947871-26-000413
5 reports for ACET
Performance horizon
Filters
Rows
Reports for ACET — sortable, filterable
Type Now
May 20, 2026
20d ago
10-K/A
NEUTRAL ★ 2/10
$7.89 $9.31▲ +18.00%▲ +16.15%$7.22 (−8.49%)
May 13, 2026
27d ago
8-K
NEUTRAL ★ 4/10
$8.41 $7.89▼ −6.18%▼ −5.47%$7.22 (−14.15%)
Apr 9, 2026
8w ago
144
NEUTRAL ★ 3/10
$6.86 $8.05▲ +17.35%▲ +14.16%$7.22 (+5.25%)
Apr 8, 2026
9w ago
144
NEUTRAL ★ 3/10
$6.55 $7.92▲ +20.92%▲ +17.40%$7.22 (+10.23%)
Mar 24, 2026
11w ago
EFFECT
NEUTRAL ★ 4/10
$6.69 $6.81▲ +1.79%▲ +2.22%$7.22 (+7.92%)
Showing 5 of 5

US Market Status

Market Closed — Opens in 7h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access